Cargando…

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabo, Amelia-Naomi, Jannier, Sarah, Becker, Guillaume, Lessinger, Jean-Marc, Entz-Werlé, Natacha, Kemmel, Véronique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067051/ https://www.ncbi.nlm.nih.gov/pubmed/33808416 http://dx.doi.org/10.3390/pharmaceutics13040470

Ejemplares similares

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
por: Jannier, Sarah, et al.
Publicado: (2020)

Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?
por: Becker, Guillaume, et al.
Publicado: (2021)

Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas
por: Pinto, Lia, et al.
Publicado: (2021)

HGG-36. HIF-2: A NEW DRUG TARGET IN PEDIATRIC HIGH-GRADE GLIOMA WITH PROMISING PRECLINICAL RESULTS
por: Fuchs, Quentin, et al.
Publicado: (2020)

The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats
por: Zhang, Feng, et al.
Publicado: (2019)

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
por: Nguyen, Aurélia, et al.
Publicado: (2017)

Glioblastoma Metabolism: Insights and Therapeutic Strategies
por: Bernhard, Chloé, et al.
Publicado: (2023)

Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study
por: Wang, Dongdong, et al.
Publicado: (2019)

Nonlinear Population Pharmacokinetics of Sirolimus in Patients With Advanced Cancer
por: Wu, K, et al.
Publicado: (2012)

Exploring Sirolimus Pharmacokinetic Variability Using Data Available from the Routine Clinical Care of Renal Transplant Patients – Population Pharmacokinetic Approach
por: Golubović, Bojana, et al.
Publicado: (2019)

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
por: Nguyen, Aurelia, et al.
Publicado: (2013)

The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia
por: Cheng, Xiaoling, et al.
Publicado: (2020)

HGG-34. A DNA DAMAGE REPAIR SIGNATURE IN PRIMARY AND RECURRENT PEDIATRIC HIGH-GRADE GLIOMAS: PROGNOSTIC AND THERAPEUTIC VALUE
por: Entz-Werle, Natacha, et al.
Publicado: (2021)

Sirolimus in lymphangioleiomyomatosis: A case in point for research in ‘orphan’ diseases
por: Koul, Parvaiz A, et al.
Publicado: (2019)

Hypoxia Inducible Factors’ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches
por: Fuchs, Quentin, et al.
Publicado: (2020)

HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022)

Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants
por: Emoto, C, et al.
Publicado: (2015)

Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability
por: Pierrevelcin, Marina, et al.
Publicado: (2020)

Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects
por: Zha, Jiuhong, et al.
Publicado: (2022)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE)
por: de Tersant, Marie, et al.
Publicado: (2020)

Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas
por: Nazon, Charlotte, et al.
Publicado: (2022)

Initial dose recommendation for sirolimus in paediatric kaposiform haemangioendothelioma patients based on population pharmacokinetics and pharmacogenomics
por: Chen, Xiao, et al.
Publicado: (2020)

Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus
por: Harbers, Veroniek E. M., et al.
Publicado: (2023)

Sirolimus-induced pneumonitis
por: Singh, U., et al.
Publicado: (2009)

Lymphedema attributed to sirolimus
por: Ardalan, Mohammad-Reza
Publicado: (2013)

Population Pharmacokinetics and Initial Dose Optimization of Sirolimus Improving Drug Blood Level for Seizure Control in Pediatric Patients With Tuberous Sclerosis Complex
por: Chen, Xiao, et al.
Publicado: (2021)

Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients
por: Maximova, Natalia, et al.
Publicado: (2022)

Autophagy in kidney transplants of sirolimus treated recipients
por: Bhayana, Sagar, et al.
Publicado: (2017)

LGG-16. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
por: Courant, Marie, et al.
Publicado: (2022)

TBIO-17. INTEGRATIVE ANALYSES OF BRAFv600e MUTATED GLIOMAS: FROM MOLECULAR BIOLOGY TO RADIOLOGY AND TREATMENTS
por: Lhermitte, Benoit, et al.
Publicado: (2020)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
por: Chen, Xiao, et al.
Publicado: (2021)

Sirolimus in the treatment of kaposiform lymphangiomatosis
por: Zhou, Jiangyuan, et al.
Publicado: (2021)

Quality of pharmacokinetic research in oncology.
por: Siderov, J., et al.
Publicado: (1995)

Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content
por: Emoto, C, et al.
Publicado: (2013)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

The combined use of sirolimus and cyclosporin in the management of refractory minimal change nephropathy: ‘a novel use of sirolimus’
por: Davison, Rachel, et al.
Publicado: (2009)

Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
por: Namba, Masashi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kp4m8v7niqr6hp6ee8ebpmokdk